Evidence map›Paper›PMID 28319148›Full record

SynthesisPloS one2017

The incremental benefit of EUS for identifying unresectable disease among adults with pancreatic adenocarcinoma: A meta-analysis.

Paul D James, Zhao Wu Meng, Mei Zhang, Paul J Belletrutti, Rachid Mohamed, William Ghali, Derek J Roberts, Guillaume Martel, Steven J Heitman

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Endoscopic ultrasonography for pancreatic solid lesions.Journal of medical ultrasonics (2001) · 2020
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paul D JamesDepartment of Medicine and the Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Canada.
Zhao Wu MengDepartment of Medicine and the Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Canada.ORCID http://orcid.org/0000-0003-3589-2208
Mei ZhangDepartment of Community Health Sciences, University of Calgary, Calgary, Canada.
Paul J BelletruttiDepartment of Community Health Sciences, University of Calgary, Calgary, Canada.
Rachid MohamedDepartment of Community Health Sciences, University of Calgary, Calgary, Canada.
William GhaliDepartment of Community Health Sciences, University of Calgary, Calgary, Canada.
Derek J RobertsDepartment of Surgery, University of Calgary, Calgary, Canada.
Guillaume MartelDepartment of Surgery, University of Ottawa, Ottawa, Canada.
Steven J HeitmanDepartment of Community Health Sciences, University of Calgary, Calgary, Canada.
University of Calgary · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND STUDY

aimsIt is unclear to what extent EUS influences the surgical management of patients with pancreatic adenocarcinoma. This systematic review sought to determine if EUS evaluation improves the identification of unresectable disease among adults with pancreatic adenocarcinoma. PATIENTS AND

methodsWe searched MEDLINE, EMBASE, bibliographies of included articles and conference proceedings for studies reporting original data regarding surgical management and/or survival among patients with pancreatic adenocarcinoma, from inception to January 7th 2017. Our main outcome was the incremental benefit of EUS for the identification of unresectable disease (IBEUS). The pooled IBEUS were calculated using random effects models. Heterogeneity was explored using stratified meta-analysis and meta-regression.

resultsAmong 4,903 citations identified, we included 8 cohort studies (study periods from 1992 to 2007) that examined the identification of unresectable disease (n = 795). Random effects meta-analysis suggested that EUS alone identified unresectable disease in 19% of patients (95% confidence interval [CI], 10-33%). Among those studies that considered portal or mesenteric vein invasion as potentially resectable, EUS alone was able to identify unresectable disease in 14% of patients (95% CI 8-24%) after a CT scan was performed. LIMITATIONS: The majority of the included studies were retrospective.

conclusionsEUS evaluation is associated with increased identification of unresectable disease among adults with pancreatic adenocarcinoma.

Indexed as

AdenocarcinomaAdultEndosonographyHumansPancreatic Neoplasms

Identifiers

PMID28319148
PMCPMC5358870
OpenAlexW2601635842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.